These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36119088)

  • 41. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
    Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
    J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel method for determining antibody-dependent cellular phagocytosis.
    Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
    J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
    Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
    Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineered Fc-glycosylation switch to eliminate antibody effector function.
    Zhou Q; Jaworski J; Zhou Y; Valente D; Cotton J; Honey D; Boudanova E; Beninga J; Rao E; Wei R; Mauriac C; Pan C; Park A; Qiu H
    MAbs; 2020; 12(1):1814583. PubMed ID: 32892677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
    Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
    Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH.
    Liu Y; Lee AG; Nguyen AW; Maynard JA
    J Biol Chem; 2022 Apr; 298(4):101798. PubMed ID: 35248534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fc-Mediated Functions of Porcine IgG Subclasses.
    Paudyal B; Mwangi W; Rijal P; Schwartz JC; Noble A; Shaw A; Sealy JE; Bonnet-Di Placido M; Graham SP; Townsend A; Hammond JA; Tchilian E
    Front Immunol; 2022; 13():903755. PubMed ID: 35757698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineered antibody Fc variants with enhanced effector function.
    Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.
    Davis PM; Abraham R; Xu L; Nadler SG; Suchard SJ
    J Rheumatol; 2007 Nov; 34(11):2204-10. PubMed ID: 17787038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of immunoglobulin (Ig)G-Fc-mediated cytotoxicity by seminal plasma IgG-Fc receptor III antigens.
    Thaler CJ; McConnachie PR; McIntyre JA
    Fertil Steril; 1992 Jan; 57(1):187-92. PubMed ID: 1530924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.
    Ratelade J; Asavapanumas N; Ritchie AM; Wemlinger S; Bennett JL; Verkman AS
    Acta Neuropathol; 2013 Nov; 126(5):699-709. PubMed ID: 23995423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.
    Leoh LS; Daniels-Wells TR; Martínez-Maza O; Penichet ML
    Mol Immunol; 2015 Oct; 67(2 Pt B):407-15. PubMed ID: 26232328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
    Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.
    Shen D; Tang Y; Li S; Xu W; Zhang L
    Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):215-20. PubMed ID: 25171000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.